Latest news with #D12
Mail & Guardian
5 days ago
- Entertainment
- Mail & Guardian
Nomisupasta and Rapsody: The collab that took 13 years
Nomsa Mazwai and Rapsody in studio. Photos: Courtesy of Nomse Mazwai Nomsa Mazwai first came into contact with Rapsody when the producer 9th Wonder sampled Mazwai's music for three songs on the North Carolina, US rapper's 2012 debut album The Idea of Beautiful. The songs sampled music from Mazwai's own debut album, the self-titled Nomisupasta, released in 2010. On the song Kind of Love, Mazwai sings, 'What kind of love is your love that you only feel when you happen to be with me?' as Rapsody opens her first verse on the track with the line, 'Soweto, we feeling the love y'all.' Poignantly, Rapsody even travelled to South Africa and shot the video in Soweto, walking through the streets, hand-in-hand with groups of children, delivering her bars in front of spaza shops and in passages. Mazwai is credited as a featured artist on this song as well as In This Town and When I Have You, but 13 years later she has not received a cent in royalties from any of the three songs. The systems meant to ensure that she collected money off the use of her intellectual property failed her. 'It's not 9th Wonder or Rapsody's fault,' Mazwai explains. 'It's our government. I can't sit here and blame people for not forcing my government to do what they're supposed to do. But, you know, I prayed about it and, luckily for me, I did not take my frustrations out on the wrong people. Sisters Nomsa and Thandiswa Mazwai and US rapper Rapsody And Rapsody and I maintained a really wonderful relationship over the years. We performed together at Zone Six, but we never really spent time together and we were just in touch on social media. And so this time when she came, she came with the intention to record with me and have me on her next album.' The friendship Mazwai and Rapsody developed over the years recently led to the two of them collaborating properly for the first time, over a decade after the release of The Idea of Beautiful. Rapsody visited South Africa for a week, accompanied by a crew of collaborators to make music for her next album. The rapper has grown to become a celebrated musician, releasing several critically acclaimed albums, and working with artists like Kendrick Lamar, J Cole and Stevie Wonder. She was named Lyricist of the Year at the 2020 BET Hip Hop Awards and earlier this year she won her first Grammy Award for the song 3:AM featuring Erykah Badu, taking home the trophy for Best Melodic Rap Performance. Mazwai already had a lot of songs she had composed with just vocals and piano but hadn't started the process of producing and recording any of the music. Through Rapsody's visit she took the opportunity to work with some renowned producers and record the music for her sophomore album, which is now scheduled for release in October and is titled Surrender. One of these producers is Mr Porter, most famous for having been a member of the Detroit rap group D12 and having produced music for fellow group member and legendary rapper Eminem as well as many others including 50 Cent, Royce da 5'9', The Game, Method Man, Snoop Dogg and Jadakiss. She also got to work with Madlib, most well-known for being a frequent collaborator of the late greats MF DOOM and J Dilla as well as Freddie Gibbs and Talib Kweli. Earlier this year, Madlib and Rapsody teamed up to release the EP Madraps which is only available on vinyl and cassette tape. This week Mazwai started teasing the Mr Porter-produced single Next Week Tuesday with a 20-second snippet on her social media accounts. This will be the first single off her album and she plans to drop it on National Women's Day – 9 August. On Instagram she's credited big sister Thandiswa as creative director for the visuals but plays coy when I ask if we'll hear the sisters collaborating on Surrender: 'You will see in the album.' She does tell me that the song she recorded with Madlib will be the second single and hints that these aren't the only well-known producers she had the opportunity to work with. And of course Mazwai and Rapsody also recorded music together for both their albums. Nomsa Mazwai and Rapsody at Soweto Theatre 'God brought Rapsody into my life at the perfect time. We spent the whole week together and it really felt like it was God's special art project for 10 days. It was this incredible moment of two creatives from two parts of the world coming together. And it was just amazing for us to connect and to meet and to really get to know each other. So while we've known each other for years, I would say we got to really know each other over the last 10 days. It was such a pleasure working with her.' Mazwai even brought in the Karabo Ya Morena youth choir into the recording process and says that the Soweto teens are going to be featured on a song Rapsody's doing with another famous rapper. She resists my attempts to pry some more info about who this prominent artist could be: 'I don't want to give all the gems away, but I can tell you that they're featured on a banger alongside someone I would say is one of the forefathers of hip-hop.' I'm dying to hear what Rapsody and Nomisupasta have created, though I know all good things require time and patience. Or as Rapsody raps on When I Have You: 'Fake ones I had in my life can't find 'em / They say God got a silly way with timing.'
Cision Canada
15-07-2025
- Business
- Cision Canada
BIOVAXYS ANNOUNCES EXTENSION OF OFFERING CLOSING DATE
VANCOUVER, BC, July 15, 2025 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (" BioVaxys" or the " Company") announces an extension of its previously announced brokered private placement LIFE financing (the " Offering") consisting of a minimum of 5,714,285 units of the Company (each, a " Unit") at a post-consolidation price of $0.35 per Unit for minimum gross proceeds of $2,000,000 and a maximum of 8,571,428 Units at a post-consolidation price of $0.35 per Unit for maximum gross proceeds of up to $3,000,000. Each Unit will consist of one (1) post-consolidation common share in the capital of the Company (each, a " Post-Consolidation Common Share") and one (1) Post-Consolidation Common Share purchase warrant (each, a " Post-Consolidation Warrant"). Each Post-Consolidation Warrant will entitle the holder thereof to purchase one Post-Consolidation Common Share at a post-consolidation price of $0.50 for a period of 36 months from the closing date of the Offering. The Company engaged Enclave Capital LLC (" Enclave"), D12 Capital Markets Inc. (" D12"), and D12's affiliate, Foundation Markets Inc., to act as agents (together the " Agents"). Upon successful closing of the Offering, Enclave will receive a cash fee equal to 8% of the total proceeds received by the Company from Enclave investors (the " Enclave Fee"). In addition to the Enclave Fee, the Company will pay Enclave a cash fee of $10,000. D12 will receive a cash commission equal to 8% of the gross proceeds committed to the Company from any party introduced by the D12 and its affiliate. Such payment shall be paid by the Company in equal share to D12 as per their direction. The Company intends to use the net proceeds raised from the Offering for research and development, general corporate purposes, and working capital. Closing of the Offering is anticipated to occur no later than 45 days after this news release. Closing of the Offering and payment of the Agents' fee are subject to the satisfaction of certain conditions, including, but not limited to, acceptance by the CSE. Subject to compliance with applicable regulatory requirements and in accordance with National Instrument 45-106 – Prospectus Exemptions (" NI 45-106"), the Units issuable under the Offering will be offered for sale to purchasers in all provinces and territories of Canada, except Quebec, pursuant to the listed issuer financing exemption (" LIFE") under Part 5A of NI 45-106. The securities to be issued pursuant to the sale of the Units under the Offering will not be subject to resale restrictions in accordance with applicable Canadian securities laws (the " CSE"). There is an amended offering document dated July 14, 2025, related to the Offering that can be accessed under the Company's profile at and on the Company's website at Prospective investors should read this offering document before making an investment decision. This news release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in the United States, or in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the " U.S. Securities Act"), or any state securities laws, and may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to available exemptions therefrom. The Company affirms that it intends to undertake a consolidation of the common shares of the Company (the " Common Shares") on the basis of ten (10) pre-consolidation Common Shares for one (1) post-consolidation Common Share (the " Consolidation"), which will occur simultaneously with the Offering. The Company currently has 293,425,203 Common Shares issued and outstanding, and it is anticipated that immediately following the Consolidation, excluding Common Shares to be issued in connection with this Offering, the Company will have approximately 29,342,520 Common Shares issued and outstanding, prior to rounding of fractional Common Shares. The exercise or conversion price of the Company's convertible securities and the number of Common Shares issuable thereunder will also be proportionately adjusted upon completion of the Consolidation. No fractional Common Shares will be issued as a result of the proposed Consolidation. Any fractional Common Shares resulting from the proposed Consolidation will be rounded up in the case of a fractional interest that is one-half (1/2) of a Common Share or greater, or rounded down in the case of a fractional interest that is less than one-half (1/2) of a Common Share, to the nearest whole number of Common Shares, and no cash consideration will be paid in respect of fractional Common Shares rounded down to the nearest whole Common Share. The Company will issue a subsequent news release in respect of the proposed Consolidation to announce the effective date of the Consolidation, the new CUSIP and ISIN for the post-Consolidation Common Shares, and any other relevant details, and file all necessary documentation with the CSE in respect of the proposed Consolidation. The post-Consolidation Common Shares will continue to trade on the CSE under the Company's existing name and trading symbol. The Consolidation remains subject to requisite approvals, including acceptance by the CSE. About BioVaxys Technology Corp. BioVaxys Technology Corp. ( a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it's HapTenix© tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization for food allergy, and other immunological diseases. Through a differentiated mechanism of action, the DPX™ platform delivers instruction to the immune system to generate a specific, robust, and persistent immune response. The Company's clinical stage pipeline includes maveropepimut-S (MVP-S), based on the DPX™ platform, and in Phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers, and also delivers an innate immune activator and a universal CD4 T cell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific anti-tumor immune response. BioVaxys is also developing DPX™+SurMAGE, a dual-targeted immunotherapy combining antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously, DPX™-RSV for Respiratory Syncytial Virus, DPX+rPA for peanut allergy prophylaxis, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix© 'neoantigen' tumor cell construct platform for refractive late-stage ovarian cancer. BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the U.S. on the OTC Markets (OTCQB marketplace). For more information, visit and connect with us on X and LinkedIn. ON BEHALF OF THE BOARD Signed " James Passin" James Passin, Chief Executive Officer Phone: +1 740 358 0555 Cautionary Statements on Forward Looking Information This news release includes certain "forward-looking information" and "forward-looking statements" (collectively " forward-looking statements") within the meaning of applicable securities legislation. All statements, other than statements of historical fact, included herein, without limitation, statements relating to the future operating or financial performance of the Company, are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or "should" occur or be achieved. Forward-looking statements in this news release relate to, among other things, the proposed Consolidation, including the ratio thereof and timing thereof, and the Offering, including the size and use of proceeds, and the timing and ability of the Company to close the Offering, including obtaining approval of the Offering from the CSE. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements. Forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by BioVaxys, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that BioVaxys' vaccines will not prove to be effective and/ or will not receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval, uncertainty about whether its autologous cell vaccine immunotherapy can be developed to produce safe and effective products and, if so, whether its vaccine products will be commercially accepted and profitable, the expenses, delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses, financial and development obligations under license arrangements in order to protect its rights to its products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties. Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements and the parties have made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation, the ability of the Company to complete the Consolidation and the Offering on the terms proposed or at all, and the ability to obtain necessary approvals, including the approval of the CSE. BioVaxys does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by applicable securities laws.
The Citizen
01-06-2025
- Sport
- The Citizen
Checkmate! Die Ruiter learners make chess history
Laerskool Die Ruiter is beaming with pride after three of its learners made history by qualifying for the Gauteng Chess Championships. Taye Kaldine (13), Daniel Nkhoma (13), and 11-year-old Kgosi Menyatsoe performed exceptionally well at the D12 Chess Tournament on May 17 at The King's School West Rand and will compete on August 1 at Barble Hall in Benoni. 'They have made history in the school, and it's a first for Laerskool Die Ruiter to have three learners qualify for the Gauteng championships,' coach Hennie Kruger said. The trio also earned their D12 colours, which is a testament to their hard work and dedication. The school's chess programme has been a success, with initially 33 learners who took on the challenge. The first competition took place earlier in May at the Roodepoort Cluster, and only seven individuals qualified to make the D12 team. Hennie praised all the learners who took on the challenge, especially the three who made it to the top. 'We're extremely proud of them,' he said. With this achievement, Laerskool Die Ruiter is solidifying its reputation as a hub for young chess talent. At Caxton, we employ humans to generate daily fresh news, not AI intervention. Happy reading!
